The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain
- 5 February 2007
- journal article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 556 (1-3), 75-83
- https://doi.org/10.1016/j.ejphar.2006.11.006
Abstract
No abstract availableFunding Information
- Ministero dell’Istruzione, dell’Università e della Ricerca
This publication has 42 references indexed in Scilit:
- GW274150, a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (iNOS), shows analgesic effects in rat models of inflammatory and neuropathic painPain, 2006
- Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI ratsNeuropharmacology, 2005
- Effect of genetic knockout or pharmacologic inhibition of neuronal nitric oxide synthase on complete Freund's adjuvant-induced persistent painPain, 2005
- The synthetic cannabinoid WIN55,212‐2 attenuates hyperalgesia and allodynia in a rat model of neuropathic painBritish Journal of Pharmacology, 2001
- MODULATION OF OXIDANT STATUS BY MELOXICAM IN EXPERIMENTALLY INDUCED ARTHRITISPharmacological Research, 1999
- Glutathione reductase activity, riboflavin status, and disease activity in rheumatoid arthritis.Annals Of The Rheumatic Diseases, 1996
- Glutathione, glutathione utilizing enzymes and thioltransferase in platelets of insulin‐dependent diabetic patients: relation with platelet aggregation and with microangiopatic complicationsEuropean Journal of Clinical Investigation, 1995
- Resiniferatoxin and its analogs provide novel insights into the pharmacology of the vanilloid (capsaicin) receptorLife Sciences, 1990
- Ethical guidelines for investigations of experimental pain in conscious animalsPain, 1983
- Mononuclear Phagocyte Antimicrobial and Antitumor Activity: the Role of Oxygen IntermediatesJournal of Investigative Dermatology, 1980